secwatch.observer — SEC 8-K summary
======================================

Issuer:     IONIS PHARMACEUTICALS INC (IONS)
CIK:        0000874015
Form:       8-K
Filed at:   2025-07-30T23:59:59+00:00
Accession:  0001140361-25-027949
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ionis Q2 revenue doubles to $452M; raises FY 2025 guidance, TRYNGOLZA sales $19M
--------------------------------------------------------------------------------

- Q2 total revenue $452M (up from $225M); GAAP income from ops $140M vs loss $66M year ago.
- TRYNGOLZA net product sales $19M in Q2, first half $26M; SPINRAZA royalties $54M, WAINUA royalties $10M.
- FY 2025 guidance raised: total revenue $825-850M (from $725-750M); TRYNGOLZA sales guided at $75-80M.
- Donidalorsen expected approval Aug 21, 2025; Phase 3 olezarsen sHTG data due September.
- Received $280M upfront from sapablursen license; cash & investments $2.3B; CFO raised non-GAAP op loss guidance to $300-325M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874015/000114036125027949/0001140361-25-027949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874015/000114036125027949/ef20052929_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-027949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer